1. Executive Summary
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Aptamer Market
4. Market Overview
    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Aptamer Market Analysis and Forecast, 2023-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. COVID-19 Pandemic Impact on Industry
6. Aptamer Market Analysis and Forecast, by Material
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Material, 2023–2031
        6.3.1. Nucleic Acid Aptamer
        6.3.2. Peptide Aptamer
    6.4. Market Attractiveness, by Material
7. Aptamer Market Analysis and Forecast, by Application
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2023–2031
        7.3.1. Research
        7.3.2. Diagnostic
        7.3.3. Therapeutics
        7.3.4. Others
        7.3.5. 7.4 Market Attractiveness, by Application
8. Global Aptamer Market Analysis and Forecast, by Technique
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Technique, 2023–2031
        8.3.1. SELEX Technique
        8.3.2. Others (MARAS, etc.)
    8.4. Market Attractiveness, by Technique
9. Global Aptamer Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2023–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Region
10. North America Aptamer Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Material, 2023–2031
        10.2.1. Nucleic Acid Aptamer
        10.2.2. Peptide Aptamer
    10.3. Market Attractiveness, by Material
    10.4. Market Value Forecast, by Application, 2023–2031
        10.4.1. Research
        10.4.2. Diagnostic
        10.4.3. Therapeutics
        10.4.4. Others
    10.5. Market Attractiveness, by Application
    10.6. Market Value Forecast, by Technique, 2023–2031
        10.6.1. SELEX Technique
        10.6.2. Others (MARAS, etc.)
    10.7. Market Attractiveness, by Technique
    10.8. Market Value Forecast, by Country, 2022–2031
        10.8.1. U.S.
        10.8.2. Canada
    10.9. Market Attractiveness Analysis
        10.9.1. By Material
        10.9.2. By Application
        10.9.3. By Technique
        10.9.4. By Country
11. Europe Aptamer Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Material, 2023–2031
        11.2.1. Nucleic Acid Aptamer
        11.2.2. Peptide Aptamer
    11.3. Market Attractiveness, by Material
    11.4. Market Value Forecast, by Application, 2023–2031
        11.4.1. Research
        11.4.2. Diagnostic
        11.4.3. Therapeutics
        11.4.4. Others
    11.5. Market Attractiveness, by Application
    11.6. Market Value Forecast, by Technique, 2023–2031
        11.6.1. SELEX Technique
        11.6.2. Others (MARAS, etc.)
    11.7. Market Attractiveness, by Technique
    11.8. Market Value Forecast, by Country/Sub-region, 2022–2031
        11.8.1. Germany
        11.8.2. U.K.
        11.8.3. France
        11.8.4. Italy
        11.8.5. Spain
        11.8.6. Rest of Europe
    11.9. Market Attractiveness Analysis
        11.9.1. By Material
        11.9.2. By Application
        11.9.3. By Technique
        11.9.4. By Country/Sub-region
12. Asia Pacific Aptamer Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Material, 2023–2031
        12.2.1. Nucleic Acid Aptamer
        12.2.2. Peptide Aptamer
    12.3. Market Attractiveness, by Material
    12.4. Market Value Forecast, by Application, 2023–2031
        12.4.1. Research
        12.4.2. Diagnostic
        12.4.3. Therapeutics
        12.4.4. Others
    12.5. Market Attractiveness, by Application
    12.6. Market Value Forecast, by Technique, 2023–2031
        12.6.1. SELEX Technique
        12.6.2. Others (MARAS, etc.)
    12.7. Market Attractiveness, by Technique
    12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
        12.8.1. China
        12.8.2. Japan
        12.8.3. India
        12.8.4. Australia & New Zealand
        12.8.5. Rest of Asia Pacific
    12.9. Market Attractiveness Analysis
        12.9.1. By Material
        12.9.2. By Application
        12.9.3. By Technique
        12.9.4. By Country/Sub-region
13. Latin America Aptamer Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Material, 2023–2031
        13.2.1. Nucleic Acid Aptamer
        13.2.2. Peptide Aptamer
    13.3. Market Attractiveness, by Material
    13.4. Market Value Forecast, by Application, 2023–2031
        13.4.1. Research
        13.4.2. Diagnostic
        13.4.3. Therapeutics
        13.4.4. Others
    13.5. Market Attractiveness, by Application
    13.6. Market Value Forecast, by Technique, 2023–2031
        13.6.1. SELEX Technique
        13.6.2. Others (MARAS, etc.)
    13.7. Market Attractiveness, by Technique
    13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
        13.8.1. Brazil
        13.8.2. Mexico
        13.8.3. Rest of Latin America
    13.9. Market Attractiveness Analysis
        13.9.1. By Material
        13.9.2. By Application
        13.9.3. By Technique
        13.9.4. By Country/Sub-region
14. Middle East & Africa Aptamer Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Material, 2023–2031
        14.2.1. Nucleic Acid Aptamer
        14.2.2. Peptide Aptamer
    14.3. Market Attractiveness, by Material
    14.4. Market Value Forecast, by Application, 2023–2031
        14.4.1. Research
        14.4.2. Diagnostic
        14.4.3. Therapeutics
        14.4.4. Others
    14.5. Market Attractiveness, by Application
    14.6. Market Value Forecast, by Technique, 2023–2031
        14.6.1. SELEX Technique
        14.6.2. Others (MARAS, etc.)
    14.7. Market Attractiveness, by Technique
    14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
        14.8.1. GCC Countries
        14.8.2. South Africa
        14.8.3. Rest of Middle East & Africa
    14.9. Market Attractiveness Analysis
        14.9.1. By Material
        14.9.2. By Application
        14.9.3. By Technique
        14.9.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. AM Biotech
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Aptagen, LLC
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Aptamer Group
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Aptamer Science, Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Pfizer Inc.
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Base Pair Biotechnologies
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. CD Genomics
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. NeoVentures Biotechnology Inc.
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. NAXXON Pharma
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Aptus Biotech
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview
        15.3.11. TriLink Bio Technologies, LLC
            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.11.2. Product Portfolio
            15.3.11.3. Financial Overview
            15.3.11.4. SWOT Analysis
            15.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			